17,261 trials
Friedreich Ataxia
Primary: Change From Baseline in the Inverse Time to Complete the 9-Hole Peg Test (9-HPT-1) — 0.00038; -0.00017; -0.00032 1/seconds — p=>0.999
Latent Tuberculosis Bacteriology and Histology Unknown · Latent Tuberculosis
Primary: Number and Percentage of Unsolicited and Solicited Adverse Events Recorded Post Day 0 Vaccination. — 7; 8; 15; 15 Participants
HER2-Positive Early Stage Breast Cancer
Primary: Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation — 16…
Type 1 Diabetes
Primary: Brain Glycogen Turnover Rate — 0.31; 0.28 mg/kg/min
Systemic Lupus Erythematosus
Primary: Maximum Concentration of Anifrolumab in Serum After First Dose — 14.058; 28.115 mcg/mL
ALS · Amyotrophic Lateral Sclerosis · Lou Gehrig's Disease
Primary: Number of Patients Tolerant to Study Drug — 6; 12 Participants — p=0.602
HIV Infections
Primary: Proportion of Participants With New Grade 3 or Greater Adverse Events — 0; 0 proportion of participants
Prostate Cancer
Primary: Percent Change Assessed by FACBC PET Scan — 3.2; 23.5 percent change of SUVmax
Gastrointestinal Problems · Autism Spectrum Disorders
Primary: Gastrointestinal Symptom Responsiveness Scale (GSRS) — 2.74; 1.31 units on a scale — p=<0.001
Head and Neck Cancer
Primary: Overall Response Rate (ORR) — 1; 14; 15; 5 participants
Osteoarthritis, Knee · Pain
Primary: Primary Efficacy Endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 35 — -130.7; -159.7; -99.0…
Fabry Disease
Primary: Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in…
Influenza
Primary: Number of Participants With Immediate Unsolicited Adverse Events (AE) After Vaccination — 0; 0; 0 Participants
Cocaine Addiction
Primary: Cocaine Use — 58.9; 71.57; 69.63; 121.25 Dollar amounts of cocaine use
Acute GVHD
Primary: Percentage of Participants With Complete or Partial Response (CR/PR) to Acute GVHD Treatment — 35; 46; 19; 17 Participants